I went back and did a statistical comparison of the # of test performed on BudGenius QOQ. Q1 = 80 tests. Q2 = 79 tests. Considering revenue was $10,099 during Q1, I would be surprised to see a bump in revenue, unless dispensaries electing testing services decided not to post tests results online (unlikely, IMO). So nothing from a revenue perspective to really get excited here, based on testing.

However, the way forward looks favorable based on information from the latest 10Q, "Consolidation in the quantity of regional cannabis dispens
aries is occurring in mature markets, leading to an expected decrease in revenue potential for products and services based on dispensary density (such as advertising and location portals), in addition to an expected increase in
revenue potential for products and services based on recurring patient services, education, and medicine safety (such as the BudGenius product platform). BG Medical expects these trends to continue in a similar manner to many market lifecycles in which newly implemented technologies lower long-term operational costs, and create a price-competitive marketplace that becomes reliant on
the efficiency of underlying technology platforms."